Product
  • Product
  • Supplier
  • Inquiry
    Home > Biocon gets eight observations for two new units in Bengaluru

    Biocon gets eight observations for two new units in Bengaluru

    Chemical Weekly 2019-10-14

    Biocon_facility


    Biotechnology major, Biocon, said it has received a total of eight observations from the US health regulator for its two new biologics manufacturing facilities in Bengaluru.


    The United States Food and Drug Administration (USFDA) conducted a pre-approval inspection (PAI) at two of the company’s new biologics manufacturing facilities in Bengaluru from September 10-19, 2019, Biocon said in a filing to the stock exchange. The inspection included a new drug substance and a drug product unit, it added.


    “At the conclusion of the inspection, we received a Form 483 with four observations for the new drug substance facility, three observations for the new drug product facility and one general observation,” a Biocon spokesperson said in a statement. The company is confident of addressing these observations effectively through a Corrective and Preventive Action (CAPA) plan, expeditiously, it added.


    The company did not provide any details about the observations made by the US regulator.

    Share to:
    Disclaimer: Echemi reserves the right of final explanation and revision for all the information.

    Scan the QR Code to Share

    Suggestions
    Email:
    Message:
    Send Message